Skip to main content

Volume 3 Supplement 2

21st European Workshop for Rheumatology Research

  • Meeting abstract
  • Published:

Development of a doxycycline inducible AAV vector for long term in vivo viral IL-10 gene transfer in rheumatoid arthritis


The recent development of AAV vectors (adeno-associated virus) offers new perspectives for cytokine gene transfer in RA as they are non pathogenic and allow long term transgene expression in vivo. Moreover, we propose to regulate vIL-10 expression with tetracycline derivative (tetON system). The purpose of this study was to assess the potential long-term gene expression regulation of a recombinant AAV vector expressing vIL-10 in human rheumatoid synovial tissue and its efficiency in collagen-induced arthritis (CIA).


The AAV-tetON-vIL10 vector contains two transcriptional units oriented in opposite directions, with a central bi-directional SV40 polyA. Sequences encoding the transcriptional activator rtTA, which confers doxycycline transgene induction, is inserted downstream a retroviral LTR promoter. A minimal human CMV promoter, flanked with tetracycline operator motifs, controls the transcription of vIL-10. Human RA synoviocytes were infected in vitro with AAV-tetON-vIL10 (500 MOI) and vIL-10 secretion was assessed by ELISA after addition of 5 μg/ml doxycycline (dox). Therapeutic efficiency of the vector was achieved after intra-muscular injection (1.5 × 109 pi) in DBA1 mice with CIA in the presence of doxycycline in the drinking water (0.2 mg/ml).


Viral IL-10 secretion by RA synoviocytes was increased 40-fold in presence of dox (233 ng/ml/106 cells) and returned to basal level 24 hr after dox removal. In CIA, serum vIL-10 increased to 0.38 ng/ml, 5 weeks after gene transfer in animals under diet dox. RT-PCR analysis showed vIL-10 transcription in the muscle up to 14 weeks, without diffusion in other organs. We observed a decrease of CIA incidence (30% versus 89% in AAV-GFP injected control group) and of paw swelling (1.68 ± 0.04 versus 1.81 ± 0.15 on day 35 post-immunization, P < 0.0003).


AAV vectors conferred safe and inducible long-term expression of vIL-10. These data support AAV-tetON-vIL10 as a therapeutical tool for gene therapy in RA.

Author information

Authors and Affiliations


Rights and permissions

Reprints and permissions

About this article

Cite this article

Apparailly, F., Noël, D., Millet, V. et al. Development of a doxycycline inducible AAV vector for long term in vivo viral IL-10 gene transfer in rheumatoid arthritis. Arthritis Res Ther 3 (Suppl 2), P091 (2001).

Download citation

  • Received:

  • Published:

  • DOI: